Cluster composition

Functions

CategoryNameIntersectionWithQueryPValueGenesInTermGenesInQueryGenesInTermInQueryID
Domain-

AMIGO3 PRAMEF17

9.79e-03321923.80.10.10
DomainL_dom-like

AMIGO3 PRAMEF17

1.02e-0232892IPR032675
ToppCellPND07-28-samps-Mesenchymal-Matrix_fibroblast-mesenchymal_C|PND07-28-samps / Age Group, Lineage, Cell class and subclass

PRAMEF17 TBR1

2.55e-0412192176de42c088988fe1a7838f96add26ee8a30e543
ToppCellCerebellum-Neuronal-Excitatory|Cerebellum / BrainAtlas - Mouse McCarroll V32

B3GNT6 TBR1

2.85e-0412892c30ba14320e9b98c9af9e4cd5a8c55380bb9ffa9
ToppCellfrontal_cortex-Non-neuronal-oligodendrocyte-Oligo-OPC_Pdgfra_Grm5|frontal_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype

P2RX7 GPR17

3.08e-041339263d2f096ae47d9b587acc6c5fbd346e5e58842b8
ToppCellBrain_organoid-organoid_Kanton_Nature-Organoid-1M-Radial_glial-RGCs_3|Organoid-1M / Sample Type, Dataset, Time_group, and Cell type.

AMIGO3 P2RX7

3.22e-04136925e209185b5f6e9347829fc9066f0b2c3711df057
ToppCellfacs-Marrow-T_cells-18m-Lymphocytic-Klrb1a/b/c(-)_NK_cell|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation

P2RX7 TBR1

4.73e-0416592eeb58d4db64ad37dc6b441eab22b05c24862e1a9
ToppCellPCW_05-06-Neuronal-Neuronal_SCP-neuro_proliferating_SCP3_(1)|PCW_05-06 / Celltypes from embryonic and fetal-stage human lung

P2RX7 GPR17

4.96e-0416992d9c3b22f62b882b8a2ea6fd9cf7afbe6d1775745
ToppCellPCW_05-06-Neuronal-Neuronal_SCP-neuro_pre_proliferating_SCP_(4)|PCW_05-06 / Celltypes from embryonic and fetal-stage human lung

P2RX7 GPR17

5.44e-041779259726bfd98f656fdcedf448a7e2e76a9bfad8285
ToppCellPCW_07-8.5-Neuronal-Neuronal_SCP-neuro_SCP_(0)|PCW_07-8.5 / Celltypes from embryonic and fetal-stage human lung

P2RX7 GPR17

5.69e-0418192fad7ba168f541ac9d04edebc206f191e48bb7e99
ToppCellSmart-start-Cell-Wel_seq-Neoplastic-Stem-like-NPC-like-NPC-like_OPC-D|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group

AMIGO3 GPR17

5.69e-0418192493a0222923ea04dadf17927c208671a046cd6df
ToppCellPCW_07-8.5-Neuronal-Neuronal_SCP-neuro_pre_proliferating_SCP_(4)|PCW_07-8.5 / Celltypes from embryonic and fetal-stage human lung

P2RX7 GPR17

5.75e-0418292bfb725fff3d20066d8ac0a6ba2f88498fcbd876e
ToppCellPCW_05-06-Neuronal-Neuronal_SCP-neuro_proliferating_SCP2_(1)|PCW_05-06 / Celltypes from embryonic and fetal-stage human lung

P2RX7 GPR17

5.75e-0418292f7f9be9c7ef8da9864d6aefe20043b26e1bb8697
ToppCellPCW_07-8.5-Neuronal-Neuronal_SCP-neuro_proliferating_SCP2_(1)|PCW_07-8.5 / Celltypes from embryonic and fetal-stage human lung

P2RX7 GPR17

5.81e-0418392e0854864d377e158a4793088d1cb6b3dbf2c805d
ToppCellPCW_07-8.5-Neuronal-Neuronal_SCP|PCW_07-8.5 / Celltypes from embryonic and fetal-stage human lung

P2RX7 GPR17

5.94e-041859256c7a0dbf141728ac76b8c90af197719942ca67c
ToppCellPCW_07-8.5-Neuronal-Neuronal_SCP-neuro_proliferating_SCP1_(1)|PCW_07-8.5 / Celltypes from embryonic and fetal-stage human lung

P2RX7 GPR17

6.00e-04186923113c85d0ac5fc46532c19b1bb71f34b985e1276
ToppCellNon-neuronal-Non-dividing-OPC-OPC|World / Primary Cells by Cluster

P2RX7 GPR17

6.20e-0418992ddf5be73912570c32c50f4ac2902da9b590526f8
ToppCellNon-neuronal-Non-dividing-OPC-OPC-30|World / Primary Cells by Cluster

P2RX7 GPR17

6.20e-0418992313d165fad541ec6e8dd524b88856e2c93eeb681
ToppCellNon-neuronal-Non-dividing-OPC|World / Primary Cells by Cluster

P2RX7 GPR17

6.20e-041899213848a031ab896b4b24c8319e4745b9b17ff9cfd
ToppCellFetal_brain-fetalBrain_Zhong_nature-GW16-OPC_related-OPC|GW16 / Sample Type, Dataset, Time_group, and Cell type.

P2RX7 GPR17

6.39e-04192925d9bc234f01c73b2531edf8960588d5b6cf260a7
ToppCellFetal_brain-fetalBrain_Zhong_nature-GW16-OPC_related|GW16 / Sample Type, Dataset, Time_group, and Cell type.

P2RX7 GPR17

6.39e-0419292e6d115143ced6a0d9fe7c98acd3f730bac83f66b
ToppCellrenal_cortex_nuclei-CKD+DKD_normotensive-Immune-Myeloid-Monocytic-Monocyte-derived_Cell|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group

P2RX7 TBC1D22A

6.59e-041959262dc745e1aa3e2e58afa16c7bb2cf9b03d4e8105
ToppCellSigmoid-NK_cell|Sigmoid / Region, Cell class and subclass

AMIGO3 P2RX7

6.87e-0419992653965a8bb09abcab7d275b01d361b7b4e3fdd58
ToppCellSigmoid-NK_cell-NK|Sigmoid / Region, Cell class and subclass

AMIGO3 P2RX7

6.87e-04199925aa943ef7a1764ce4e95a7163aaabe2ee89eb870
ToppCellSigmoid-(0)_NK_cell-(00)_NK|Sigmoid / shred on region, Cell_type, and subtype

AMIGO3 P2RX7

6.87e-0419992689e8675d2d40cfb1bd200767a35dcc6664214d9
ToppCellSigmoid-(0)_NK_cell|Sigmoid / shred on region, Cell_type, and subtype

AMIGO3 P2RX7

6.87e-04199925be944da7a6c5f6076ed508a64f77d90836becd7
ToppCell3'-GW_trimst-2-SmallIntestine-Neuronal-Glial_immature|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract

P2RX7 GPR17

6.87e-04199921761669ec514fdb4175042f11b9a31fa5687fc2b
ToppCellFetal_brain-fetalBrain_Zhong_nature-GW26-OPC_related|GW26 / Sample Type, Dataset, Time_group, and Cell type.

P2RX7 GPR17

6.93e-042009246521d83b917b0357601db8783c8da6b73730d60
ToppCellFetal_brain-fetalBrain_Zhong_nature-GW23-OPC_related|GW23 / Sample Type, Dataset, Time_group, and Cell type.

P2RX7 GPR17

6.93e-0420092439265194cb08d1373296bf8684cc31294cecb20
ToppCellFetal_brain-fetalBrain_Zhong_nature-GW23-OPC_related-OPC|GW23 / Sample Type, Dataset, Time_group, and Cell type.

P2RX7 GPR17

6.93e-04200920450a79c5fae5ccacdb990ae674e4734ef0c3691
ToppCellFetal_brain-fetalBrain_Zhong_nature-GW26-OPC_related-OPC|GW26 / Sample Type, Dataset, Time_group, and Cell type.

P2RX7 GPR17

6.93e-042009202594c1edbc9f2cf831639cd83363abd2551cb94
ComputationalGenes upregulated in subsets of cells of a given type within various tumors

P2RX7 GPR17

3.14e-045062GAVISH_3CA_MALIGNANT_METAPROGRAM_27_OLIGO_PROGENITOR
ComputationalNeighborhood of ETV3

P2RX7 TBC1D22A

5.32e-046562MORF_ETV3
DrugSulfamethazine sodium salt [1981-58-4]; Up 200; 13.4uM; MCF7; HT_HG-U133A

P2RX7 ANGEL2 TBC1D22A

4.93e-05194933422_UP
DrugDiprophylline [479-18-5]; Up 200; 15.8uM; PC3; HT_HG-U133A

ANGEL2 GPR17 TBC1D22A

5.08e-05196935063_UP
DrugMafenide hydrochloride [138-37-4]; Up 200; 18uM; PC3; HT_HG-U133A

ANGEL2 TBC1D22A TBR1

5.31e-05199935079_UP
DrugChrysin [480-40-0]; Up 200; 15.8uM; MCF7; HT_HG-U133A

P2RX7 ANGEL2 TBC1D22A

5.31e-05199935505_UP
Drugtert-butyl acetate

GPR17 TBR1

2.27e-045892CID000010908
Drug2-(aminomethyl)pyrrolidine

P2RX7 GPR17

1.73e-0316192CID000072032
DrugAl 6629

P2RX7 TBR1

1.77e-0316392CID004369171
DrugStrophantine octahydrate [11018-89-6]; Down 200; 5.4uM; MCF7; HT_HG-U133A

ANGEL2 TBC1D22A

2.09e-03177925026_DN
Drugvalinomycin; Up 200; 0.1uM; PC3; HT_HG-U133A

ANGEL2 TBC1D22A

2.13e-03179925962_UP
DrugPropofol [2078-54-8]; Down 200; 22.4uM; MCF7; HT_HG-U133A

ANGEL2 TBC1D22A

2.42e-03191923386_DN
DrugParbendazole [14255-87-9]; Up 200; 16.2uM; PC3; HT_HG-U133A

P2RX7 GPR17

2.50e-03194923799_UP
DrugOxybutynin chloride [1508-65-2]; Down 200; 10.2uM; MCF7; HT_HG-U133A

RNF31 TBC1D22A

2.50e-03194923168_DN
DrugSkimmianine [83-95-4]; Up 200; 15.4uM; MCF7; HT_HG-U133A

P2RX7 TBC1D22A

2.50e-03194926066_UP
DrugSulfameter [651-06-9]; Down 200; 14.2uM; PC3; HT_HG-U133A

RNF31 TBC1D22A

2.50e-03194925732_DN
DrugNorethindrone [68-22-4]; Up 200; 13.4uM; PC3; HT_HG-U133A

GPR17 TBC1D22A

2.50e-03194925055_UP
DrugFlurandrenolide [1524-88-5]; Up 200; 9.2uM; PC3; HT_HG-U133A

P2RX7 TBC1D22A

2.50e-03194923679_UP
DrugDrofenine hydrochloride [548-66-3]; Up 200; 11.4uM; MCF7; HT_HG-U133A

RNF31 TBC1D22A

2.53e-03195923455_UP
DrugMetyrapone [54-36-4]; Down 200; 17.6uM; MCF7; HT_HG-U133A

TBC1D22A TBR1

2.53e-03195925667_DN
DrugTiaprofenic acid [33005-95-7]; Down 200; 15.4uM; MCF7; HT_HG-U133A

ANGEL2 TBC1D22A

2.53e-03195922852_DN
Drug(S)-propranolol hydrochloride [4199-10-4]; Up 200; 13.6uM; MCF7; HT_HG-U133A

ANGEL2 TBC1D22A

2.53e-03195925444_UP
DrugMethacholine chloride [62-51-1]; Up 200; 20.4uM; MCF7; HT_HG-U133A

RNF31 TBC1D22A

2.53e-03195923452_UP
DrugClindamycin hydrochloride [21462-39-5]; Down 200; 8.6uM; MCF7; HT_HG-U133A

RNF31 TBC1D22A

2.53e-03195927172_DN
DrugPropoxycaine hydrochloride [550-83-4]; Down 200; 12uM; MCF7; HT_HG-U133A

RNF31 TBC1D22A

2.53e-03195923583_DN
DrugFlorfenicol [73231-34-2]; Down 200; 11.2uM; HL60; HT_HG-U133A

ANGEL2 TBC1D22A

2.53e-03195923083_DN
DrugPipenzolate bromide [125-51-9]; Down 200; 9.2uM; MCF7; HT_HG-U133A

ANGEL2 TBC1D22A

2.53e-03195926821_DN
DrugCephalexin monohydrate [23325-78-2]; Up 200; 11uM; HL60; HT_HG-U133A

P2RX7 TBC1D22A

2.53e-03195921273_UP
DrugRapamycin; Down 200; 0.1uM; HL60; HT_HG-U133A

P2RX7 TBC1D22A

2.53e-03195926180_DN
DrugFillalbin [4540-25-4]; Down 200; 13.8uM; MCF7; HT_HG-U133A

ANGEL2 TBC1D22A

2.53e-03195922813_DN
DrugPrazosin hydrochloride [19237-84-4]; Down 200; 9.6uM; PC3; HT_HG-U133A

RNF31 TBC1D22A

2.55e-03196926315_DN
DrugLomefloxacin hydrochloride [98079-52-8]; Up 200; 10.4uM; PC3; HT_HG-U133A

GPR17 TBC1D22A

2.55e-03196924281_UP
Drug2-propylpentanoic acid; Down 200; 200uM; MCF7; HT_HG-U133A

ANGEL2 TBC1D22A

2.55e-03196925574_DN
DrugPhensuximide [86-34-0]; Up 200; 21.2uM; PC3; HT_HG-U133A

ANGEL2 GPR17

2.55e-03196925097_UP
DrugICI 182,780; Down 200; 1uM; HL60; HT_HG-U133A

RNF31 TBC1D22A

2.55e-03196921146_DN
DrugTolbutamide [64-77-7]; Down 200; 14.8uM; PC3; HT_HG-U133A

GPR17 TBC1D22A

2.55e-03196924540_DN
DrugTrimethoprim [738-70-5]; Down 200; 13.8uM; PC3; HT_HG-U133A

RNF31 TBC1D22A

2.55e-03196927377_DN
DrugRisperidone [106266-06-2]; Up 200; 9.8uM; MCF7; HT_HG-U133A

ANGEL2 TBC1D22A

2.55e-03196923508_UP
DrugAcyclovir [59277-89-3]; Up 200; 17.8uM; PC3; HT_HG-U133A

GPR17 TBR1

2.55e-03196924683_UP
DrugPyrantel tartrate [33401-94-4]; Up 200; 11.2uM; PC3; HT_HG-U133A

ANGEL2 TBC1D22A

2.55e-03196925088_UP
DrugBetazole hydrochloride; Up 200; 27uM; PC3; HT_HG-U133A

ANGEL2 GPR17

2.55e-03196926344_UP
DrugAllantoin [97-59-6]; Up 200; 25.2uM; PC3; HT_HG-U133A

RNF31 TBC1D22A

2.55e-03196925052_UP
Drug(1)-Nipecotic acid [498-95-3]; Down 200; 31uM; HL60; HT_HG-U133A

RNF31 TBC1D22A

2.55e-03196923121_DN
DrugCrotamiton [483-63-6]; Down 200; 19.6uM; PC3; HT_HG-U133A

GPR17 TBC1D22A

2.55e-03196924628_DN
DrugNialamide [51-12-7]; Up 200; 13.4uM; MCF7; HT_HG-U133A

ANGEL2 TBR1

2.55e-03196923871_UP
DrugCP-319743 [172078-87-4]; Down 200; 10uM; PC3; HT_HG-U133A

ANGEL2 GPR17

2.55e-03196927491_DN
DrugDomperidone maleate; Down 200; 7.4uM; HL60; HT_HG-U133A

RNF31 TBC1D22A

2.55e-03196921301_DN
DrugFolinic acid calcium salt [6035-45-6]; Down 200; 7.8uM; PC3; HT_HG-U133A

ANGEL2 GPR17

2.55e-03196923703_DN
Drug(1)-Nipecotic acid [498-95-3]; Down 200; 31uM; MCF7; HT_HG-U133A

RNF31 TBC1D22A

2.58e-03197925999_DN
DrugAdrenosterone [382-45-6]; Up 200; 13.4uM; PC3; HT_HG-U133A

ANGEL2 TBC1D22A

2.58e-03197925045_UP
DrugTodralazine hydrochloride [3778-76-5]; Up 200; 14.8uM; MCF7; HT_HG-U133A

ANGEL2 TBC1D22A

2.58e-03197925512_UP
DrugRapamycin; Down 200; 0.1uM; HL60; HT_HG-U133A

RNF31 TBC1D22A

2.58e-03197921183_DN
DrugPhenformin hydrochloride [834-28-6]; Down 200; 16.6uM; HL60; HT_HG-U133A

RNF31 TBC1D22A

2.58e-03197922350_DN
Drug0173570-0000 [211245-44-2]; Up 200; 1uM; MCF7; HT_HG-U133A

ANGEL2 TBC1D22A

2.58e-03197924715_UP
DrugEtilefrine hydrochloride [534-87-2]; Down 200; 18.4uM; MCF7; HT_HG-U133A

RNF31 TBC1D22A

2.58e-03197927350_DN
DrugKanamycin A sulfate [25389-94-0]; Up 200; 6.8uM; PC3; HT_HG-U133A

P2RX7 TBR1

2.58e-03197924625_UP
DrugTrichlorfon [52-68-6]; Up 200; 15.6uM; MCF7; HT_HG-U133A

ANGEL2 TBC1D22A

2.58e-03197921675_UP
DrugCytisine (-) [485-35-8]; Down 200; 21uM; MCF7; HT_HG-U133A

RNF31 TBC1D22A

2.58e-03197926217_DN
DrugMexiletine hydrochloride [5370-01-4]; Down 200; 18.6uM; MCF7; HT_HG-U133A

ANGEL2 TBC1D22A

2.58e-03197922324_DN
DrugDimethadione [695-53-4]; Down 200; 31uM; MCF7; HT_HG-U133A

RNF31 TBR1

2.58e-03197925668_DN
Drugrotenone; Down 200; 1uM; PC3; HT_HG-U133A

GPR17 TBC1D22A

2.58e-03197925948_DN
DrugTriprolidine hydrochloride [550-70-9]; Down 200; 12.8uM; HL60; HT_HG-U133A

P2RX7 TBC1D22A

2.58e-03197922376_DN
DrugPirenperone [ 75444-65-4]; Up 200; 10.2uM; PC3; HT_HG-U133A

P2RX7 TBC1D22A

2.58e-03197924679_UP
DrugNorgestrel-(-)-D [797-63-7]; Down 200; 12.8uM; MCF7; HT_HG-U133A

RNF31 TBC1D22A

2.58e-03197924730_DN
DrugFlupentixol dihydrochloride cis-(Z) [2413-38-9]; Up 200; 7.8uM; PC3; HT_HG-U133A

GPR17 TBC1D22A

2.58e-03197926708_UP
DrugProchlorperazine dimaleate [84-02-6]; Up 200; 6.6uM; PC3; HT_HG-U133A

ANGEL2 TBR1

2.58e-03197926664_UP
DrugMethyldopate hydrochloride [2508-79-4]; Up 200; 14.6uM; MCF7; HT_HG-U133A

ANGEL2 TBC1D22A

2.58e-03197927360_UP
Drugfelodipine; Up 200; 10uM; MCF7; HG-U133A

P2RX7 TBR1

2.58e-0319792337_UP
DrugCinchonine [118-10-5]; Up 200; 13.6uM; PC3; HT_HG-U133A

ANGEL2 GPR17

2.58e-03197923988_UP
DrugVinpocetine [42971-09-5]; Down 200; 11.4uM; MCF7; HT_HG-U133A

RNF31 TBC1D22A

2.58e-03197927213_DN
DrugBenfotiamine [22457-89-2]; Up 200; 8.6uM; HL60; HT_HG-U133A

ANGEL2 TBC1D22A

2.58e-03197922177_UP
Drugchlorpromazine hydrochloride; Up 200; 1uM; MCF7; HT_HG-U133A_EA

RNF31 ANGEL2

2.58e-03197921055_UP
DrugBenzocaine [94-09-7]; Down 200; 24.2uM; MCF7; HT_HG-U133A

ANGEL2 TBC1D22A

2.58e-03197922822_DN
DrugIsoquinoline, 6,7-dimethoxy-1-methyl-1,2,3,4-tetrahydro, hydrochloride; Up 200; 16.4uM; PC3; HT_HG-U133A

ANGEL2 GPR17

2.58e-03197924226_UP
DrugPropidium iodide [25535-16-4]; Up 200; 6uM; MCF7; HT_HG-U133A

ANGEL2 TBC1D22A

2.58e-03197926277_UP
DrugN-Acetyl-DL-homocysteine Thiolactone [1195-16-0]; Down 200; 25.2uM; MCF7; HT_HG-U133A

ANGEL2 TBC1D22A

2.58e-03197923836_DN
DrugU-62066 [87151-85-7]; Down 200; 1uM; PC3; HT_HG-U133A

GPR17 TBC1D22A

2.58e-03197924553_DN
DrugNaringenine [480-41-1]; Down 200; 14.6uM; HL60; HT_HG-U133A

RNF31 TBC1D22A

2.58e-03197921342_DN
DrugEpirizole [18694-40-1]; Up 200; 17uM; PC3; HT_HG-U133A

GPR17 TBC1D22A

2.58e-03197927292_UP
DrugMethylatropine nitrate [52-88-0]; Down 200; 11uM; PC3; HT_HG-U133A

RNF31 TBC1D22A

2.58e-03197927253_DN
DrugMetoprolol-(+,-) (+)-tartrate salt [56392-17-7]; Up 200; 5.8uM; MCF7; HT_HG-U133A

TBC1D22A TBR1

2.60e-03198926106_UP
DrugTrapidil [15421-84-8]; Down 200; 19.4uM; MCF7; HT_HG-U133A

ANGEL2 TBC1D22A

2.60e-03198926515_DN
DrugBetonicine [515-25-3]; Up 200; 25.2uM; PC3; HT_HG-U133A

GPR17 TBR1

2.60e-03198924301_UP
DrugAlverine citrate salt [5560-59-8]; Up 200; 8.4uM; PC3; HT_HG-U133A

GPR17 TBR1

2.60e-03198926345_UP
DrugDosulepin hydrochloride [897-15-4]; Up 200; 12uM; PC3; HT_HG-U133A

GPR17 TBC1D22A

2.60e-03198927284_UP
DrugOxybenzone [131-57-7]; Up 200; 17.6uM; PC3; HT_HG-U133A

GPR17 TBC1D22A

2.60e-03198926309_UP
Drugfluphenazine dihydrochloride; Down 200; 10uM; PC3; HT_HG-U133A

RNF31 TBC1D22A

2.60e-03198921237_DN

Protein segments in the cluster

PeptideGeneStartEntry
RRPLYAHLACAFLWV

GPR17

171

Q13304
LPCDCRLYHLLQRWH

AMIGO3

221

Q86WK7
LYRHCRRPVLHWSFR

ANGEL2

186

Q5VTE6
YLCRWIHYRRGLVHL

PRAMEF17

166

Q5VTA0
NLDRWFHHCRPKYSF

P2RX7

261

Q99572
DFLRYRHCRHFPLLW

B3GNT6

91

Q6ZMB0
VYLCNRPLWLKFHRH

TBR1

206

Q16650
HPRDCLFYLRDWTAL

RNF31

926

Q96EP0
HFHLYVCAAFLVRWR

TBC1D22A

451

Q8WUA7